NovAccess Global Inc.

Equities

XSNX

US67001N1072

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 17:43:12 14/05/2024 BST			5-day change	1st Jan Change
0.006 ^USD	-7.69%		-4.76%	-70.15%

04-29	NovAccess Global Inc. announced that it has received $0.0265 million in funding from AJB Capital Investments LLC	CI
02-27	NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021

February 18, 2022 at 11:10 am

NovAccess Global Inc. reported earnings results for the first quarter ended December 31, 2021. For the first quarter, the company reported net loss was USD 0.143308 million compared to net income of USD 0.155114 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to basic earnings per share from continuing operations of USD 0.03 a year ago.

Diluted loss per share from continuing operations was USD 0.01 compared to diluted earnings per share from continuing operations of USD 0.02 a year ago.

Latest news about NovAccess Global Inc.

NovAccess Global Inc. announced that it has received $0.0265 million in funding from AJB Capital Investments LLC	04-28	CI
NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-27	CI
NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLC	02-26	CI
NovAccess Global Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	02-09	CI
NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory Board	11-10	CI
NovAccess Global Inc. announced that it expects to receive $10.68 million in funding from Sumner Capital Pty Ltd.	31/08/23	CI
NovAccess Global Inc. announced that it expects to receive $0.055 million in funding	15/08/23	CI
NovAccess Global Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	11/08/23	CI
NovAccess Global Inc. Partners with BCN Biosciences to Expand Immunotherapy Platform	27/07/23	CI
NovAccess Global Inc. announced that it has received $0.055 million in funding from 1800 Diagonal Lending, LLC	19/06/23	CI
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division	16/06/23	CI
NovAccess Global Inc. Enters into a Letter Agreement with AJB Capital Investments, LLC	12/06/23	CI
NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare Therapies	01/06/23	CI
NovAccess Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	15/05/23	CI
NovAccess Global Inc. announced that it has received $0.05425 million in funding from 1800 Diagonal Lending, LLC	27/04/23	CI
NovAccess Global Inc. announced that it expects to receive $0.05425 million in funding from 1800 Diagonal Lending, LLC	23/04/23	CI
NovAccess Global Inc. announced that it has received $0.07925 million in funding from 1800 Diagonal Lending, LLC	10/04/23	CI
NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	14/02/23	CI
NovAccess Global Inc. announced that it has received $0.265 million in funding	08/02/23	CI
NovAccess Global Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	10/01/23	CI
NovAccess Global Inc. Auditor Raises 'Going Concern' Doubt	09/01/23	CI
NovAccess Global Inc. announced that it has received $0.055 million in funding from 1800 Diagonal Lending, LLC	06/12/22	CI
Novaccess Global Inc. Appoints Peter Weinstein to Scientific Advisory Board	10/11/22	CI
NovAccess Global Inc. announced that it has received $0.055 million in funding from 1800 Diagonal Lending, LLC	06/11/22	CI
NovAccess Global Inc. Receives FDA Approval of Orphan Drug Application for TLR-AD1	28/10/22	CI

Chart NovAccess Global Inc.

Duration

Period

More charts

Company Profile

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patientâs own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patientâs tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVACCESS GLOBAL INC.	-70.15%	225K
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+47.13%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research